A mechanistic model of in vitro plasma activation to evaluate therapeutic kallikrein-kinin system inhibitors
Fig 7
Inhibition of BK generation via different KKS inhibitors.
a) Simulated data showing the proportion of CSL312-FXII complex to total FXII in plasma equilibrated with different concentrations of CSL312, b) normalised BK concentrations generated by DXS-mediated activation of healthy pooled plasma titrated with various KKS inhibitors, comparison of in vitro data with model output. Experimental data was adapted from Cao et al. [8].